Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
暂无分享,去创建一个
E. Cuppen | E. Smit | P. Roepman | H. Morreau | H. Gelderblom | H. Verheul | A. Huitema | E. Gort | J. D. de Groot | F. Erdkamp | M. Hendriks | C. V. van Herpen | L. Hoes | J. van de Haar | D. L. van der Velden | L. Beerepoot | V. van der Noort | M. Labots | M. Lolkema | A. Hoeben | L. Zeverijn | D. D. de Groot | E. Kerver | W. V. D. van der Graaf | H. van der Wijngaart | E. Voest | Anne M. L. Jansen | J. M. van Berge Henegouwen | Wendy J de Leng | Erik van Werkhoven
[1] C. von Kalle,et al. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. , 2021, Cancer discovery.
[2] G. Mills,et al. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer , 2021, Clinical Cancer Research.
[3] R. Bernards,et al. Thinking Differently about Cancer Treatment Regimens. , 2021, Cancer discovery.
[4] David C. Smith,et al. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors , 2021, JAMA oncology.
[5] P. Hegde,et al. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases , 2020, Modern Pathology.
[6] P. Casali,et al. Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU) , 2020, ESMO Open.
[7] Vinod Sharma,et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2020, The New England journal of medicine.
[8] S. Sleijfer,et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs , 2019, Nature.
[9] Harpreet Wasan,et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2019, The New England journal of medicine.
[10] N. Socci,et al. Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.
[11] S. Sleijfer,et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Sicklick,et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study , 2019, Nature Medicine.
[13] J. Sicklick,et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. , 2018, JCO precision oncology.
[14] S. Sleijfer,et al. Pan-cancer whole-genome analyses of metastatic solid tumours , 2018, bioRxiv.
[15] Johannes G. Reiter,et al. Minimal functional driver gene heterogeneity among untreated metastases , 2018, Science.
[16] Edward S. Kim,et al. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. , 2018, JCO precision oncology.
[17] Steven J. M. Jones,et al. Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial. , 2018 .
[18] J. Hainsworth,et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Eva Ardanaz,et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. , 2017, The Lancet. Oncology.
[20] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[21] J. Colwell. NCI-MATCH Trial Draws Strong Interest. , 2016, Cancer discovery.
[22] D. Huntsman,et al. Rare cancers: a sea of opportunity. , 2016, The Lancet. Oncology.
[23] J. Blay,et al. The value of research collaborations and consortia in rare cancers. , 2016, The Lancet. Oncology.
[24] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Gatta,et al. Rare cancers are not so rare: the rare cancer burden in Europe. , 2011, European journal of cancer.
[26] A. D’Andrea,et al. Susceptibility pathways in Fanconi's anemia and breast cancer. , 2010, The New England journal of medicine.
[27] M. Eck,et al. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. , 2009, Current opinion in cell biology.
[28] A. Feinberg,et al. Wilms' tumor as a model for cancer biology. , 2003, Methods in molecular biology.
[29] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.